DUBLIN, Ireland and PRAGUE, Czech Republic, November 30 /PRNewswire-FirstCall/ --
- Innovation to Enable Development of Functional Beverage Opportunity
Alltracel Pharmaceuticals Plc., (“Alltracel”, or “the Company”), (AIM:AP.L), the Medical Technology Company focussed on the Woundcare, Oralcare and Cardiovascular Health markets is today pleased to confirm the successful development of a highly soluble derivative of its patented cardiovascular health benefiting bioactive.
This successful technology innovation, carried out over a number of months at Alltracel’s Process Development Laboratory in Tisnov, Czech Republic, was part of Alltracel’s ongoing CVH development programme and presents a competitive advantage over other cardiovascular health dietary ingredients and bio-actives, facilitating an entry into the functional beverage industry.
Alltracel Pharmaceutical’s CEO, Tony Richardson, commented:
“The search for a soluble derivative of our patented cardiovascular health benefiting bioactive has been a scientific development priority for us over the last year. We are delighted with this significant technology breakthrough which now opens up the functional beverage market by far the most innovative and profitable sector within the functional food and nutritional marketplace.”
For Further Information Contact: Dublin: Denise Cronin Alltracel: +353-1-235-2162 press@alltracel.com London: Deborah Scott Financial Dynamics: +44-0207-831-3113 New York: Sean Leous Financial Dynamics: +1-212-850-5626 Notes to Editors:
Alltracel (AIM: AP.L) (www.alltracel.com) Alltracel Pharmaceuticals Plc (“Alltracel”) is a Medical Technology Company focussed on the Woundcare, Oralcare and Cardiovascular Health markets.
With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China. Alltracel was founded in 1996 and listed on London’s Alternative Investment Market in July 2001.
Alltracel’ has a number of patents in the areas of polysaccharide manipulation and PTFE processes and products as well as a significant collaborative R&D programme in place focussed on its markets.
In the consumer Woundcare market m-doc(TM) (Micro Dispersed Oxidized Cellulose; (www.m-doc.com)) is the trading name given to Alltracel’s patented technology which is proven as an effective and efficient haemostatic (blood-stopping) agent and is currently being marketed as the leading stops bleeding ingredient brand within recognized woundcare, and relevant first-aid brands worldwide. Alltracel’s specialist Nanotechnology subsidiary Nanopeutics(TM) is headquartered in Liberec in the Czech Republic and is dedicated to the commercialisation of Nanospider(TM) technology for the global professional and consumer woundcare markets.
Within the Cardiovascular Health market Alltracel (www.alltracelcvh.com) has developed a novel bioactive compound that, following over two years of scientific research including in vitro, pre-clinical and clinical trials, indicates cardiovascular health (CVH) benefits on its own and in combination with existing CVH products.
The end result is a pioneering, value-adding bioactive that can enhance and differentiate current cardiovascular health products and that can add benefit to current non-health benefiting nutritious finished foods.
m-doc(TM) is a trademarks of Alltracel Pharmaceuticals PLC.
Nanospider(TM) and Nanopeutics(TM) are trademarks controlled by Nanopeutics s.r.o.
Alltracel Pharmaceuticals Plc.
CONTACT: Dublin: Denise Cronin, London: Deborah Scott, New York: SeanLeous, Alltracel: +353-1-235-2162, Financial Dynamics: +44-0207-831-3113,press@alltracel.com, Financial Dynamics: +1-212-850-5626
